PBM
CRNX icon

Propel Bio Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Propel Bio Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-165,000
Closed -$5.87M – 31
2023
Q4 		$5.87M Buy
+165,000
New +$5.06M 4.87% 5

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Propel Bio Management's CRNX Position: Q1 2024 in Review

Propel Bio Management sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2024, closing a stake of 165,000 shares — an estimated $5.87M sold.

Propel Bio Management first reported a position in CRNX in Q4 2023 and held it in 1 quarter. The position peaked at $5.87M in Q4 2023. 203 funds tracked by Wall St. Rank hold CRNX as of Q1 2024.

  • Propel Bio Management reported no remaining Crinetics Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Propel Bio Management sold 165,000 Crinetics Pharmaceuticals shares in Q1 2024, an estimated $5.87M.
  • Propel Bio Management first reported a position in Crinetics Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Propel Bio Management's Crinetics Pharmaceuticals position peaked at $5.87M in Q4 2023.
  • 203 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2024.

Based on Propel Bio Management's 13F filing for Q1 2024, filed 13 May 2024.